Erica Mann - Kellanova Independent Director
K Stock | USD 57.38 0.84 1.49% |
Director
Ms. Erica L. Mann is Director of the Company. She has served as a Kellogg Director since February 2019. Ms. Mann previously served as a member of the Board of Management of Bayer AG from January 2016 to March 2018, and Bayer AG CH from January 2016 to March 2018. She was also President Consumer Health, Bayer Healthcare LLC from March 2015 to December 2015. Before joining Bayer HealthCare, Ms. Mann was President and General Manager of Pfizer Nutritional Health, a global business unit with operations in more than 80 countries, and served as a member of the Pfizer Senior Management Team from 2008 to 2011. Ms. Mann joined Pfizer upon its acquisition of Wyeth, where as Senior Vice President of Nutrition, she helped establish the shape and strategic direction of the new nutrition business unit. She also has significant experience at other Fortune 500 companies, including Ely Lily Company and Johnson Johnson, and has held leadership positions in South Africa, Australia, New Zealand, Germany, Switzerland and the United States. since 2019.
Age | 62 |
Tenure | 5 years |
Address | 412 North Wells Street, Chicago, IL, United States, 60654 |
Phone | 269 961 2000 |
Web | https://www.kellanova.com |
Kellanova Management Efficiency
The company has return on total asset of 0.0513 % which means that for every 100 dollars spent on assets, it generated a profit of $0.0513. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2035 %, implying that it made 0.2035 on every $100 invested by shareholders. Kellanova's management efficiency ratios could be used to measure how well Kellanova manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.15 this year. Return On Capital Employed is expected to rise to 0.29 this year. Change To Liabilities is expected to rise to about 496.3 M this year, although the value of Total Current Liabilities will most likely fall to about 3.2 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Muneaki Fujimoto | Japan Tobacco ADR | N/A | |
Main Koda | Japan Tobacco ADR | 67 | |
Koichiro Watanabe | Japan Tobacco ADR | 65 | |
Main Kohda | Japan Tobacco ADR | 65 | |
Motoyuki Oka | Japan Tobacco ADR | 73 | |
Yasushi Hasegawa | Japan Tobacco ADR | N/A | |
Yukiko Nagashima | Japan Tobacco ADR | 57 | |
Shigenori Ohkawa | Japan Tobacco ADR | N/A | |
James Cornell | 22nd Century Group | 57 | |
Masahiko Sato | Japan Tobacco ADR | N/A | |
Richard Sanders | 22nd Century Group | 61 | |
Toru Oguchi | Japan Tobacco ADR | N/A | |
Goichi Matsuda | Japan Tobacco ADR | N/A | |
Nora Sullivan | 22nd Century Group | 57 | |
Joseph Dunn | 22nd Century Group | 61 |
Management Performance
Return On Equity | 0.2 | ||||
Return On Asset | 0.0513 |
Kellanova Leadership Team
Elected by the shareholders, the Kellanova's board of directors comprises two types of representatives: Kellanova inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kellanova. The board's role is to monitor Kellanova's management team and ensure that shareholders' interests are well served. Kellanova's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kellanova's outside directors are responsible for providing unbiased perspectives on the board's policies.
CFA IV, Vice Planning | ||
Paul Norman, Sr. VP and President of North America | ||
Charisse Hughes, Senior Officer | ||
Gary Pilnick, Vice Chairman - Corporate Development and Chief Legal Officer | ||
Donald Mondano, Principal Accounting Officer, Vice President Corporate Controller | ||
Marcella Kain, Senior Director | ||
Mary Laschinger, Independent Director | ||
Lesley Salmon, Senior Officer | ||
Donald Knauss, Lead Independent Director | ||
Christopher Hood, Senior Vice President, President of Kellogg North America | ||
Nicolas Amaya, Senior Vice President and Presidentident, Kellogg Latin America | ||
Victor Cade, Senior America | ||
Doug Vandevelde, Senior Category | ||
Erica Mann, Independent Director | ||
Peter Rahal, President RX | ||
Fareed Khan, CFO | ||
Noel Wallace, Director | ||
Roderick Gillum, Independent Director | ||
Kurt Forche, Vice President Corporate Controller | ||
Maria Mejia, Senior Vice President and Presidentident, Kellogg Latin America | ||
Alistair Hirst, Senior Vice President - Global Supply Chain | ||
Richard Dreiling, Independent Director | ||
Ann Korologos, Independent Director | ||
John Bryant, Chairman, CEO and Chairman of Executive Committee | ||
John Min, Senior Secretary | ||
J Schlotman, Independent Director | ||
Joel Kooi, VP Treasurer | ||
Lauren Beck, Senior Relations | ||
Carter Cast, Independent Director | ||
Clive Sirkin, Senior Vice President Chief Growth Officer | ||
Melissa Howell, Senior Vice President - Global Human Services of the company | ||
Gordon Gund, Lead Independent Director | ||
Steven Cahillane, Chairman of the Board, President, Chief Executive Officer | ||
Rebecca Boustead, Director Pacific | ||
John Dillon, Independent Director | ||
Shumit Kapoor, Senior Vice President and Presidentident - Kellogg Asia Pacific, Middle East and Africa | ||
James Jenness, Non-Executive Director | ||
Stephanie Burns, Independent Director | ||
La Tabron, Independent Director | ||
Ronald Dissinger, CFO and Sr. VP | ||
David Lawlor, Senior Vice President, President, Kellogg Europe | ||
Zachary Gund, Independent Director | ||
G Gund, Independent Director | ||
Amit Banati, Senior Vice President and Presidentident, Asia Pacific | ||
Michael Hunter, VP Sales | ||
Rogelio Rebolledo, Independent Director | ||
Cynthia Milligan, Independent Director | ||
Carolyn Tastad, Independent Director | ||
Monica McGurk, Senior Vice President Chief Growth Officer | ||
Kris Bahner, Senior Officer | ||
Rodrigo Lance, Senior Vice President - Global Supply Chain | ||
Samantha Long, Senior Vice President - Global Human Resources |
Kellanova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kellanova a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.2 | ||||
Return On Asset | 0.0513 | ||||
Profit Margin | 0.07 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 25.7 B | ||||
Shares Outstanding | 341.76 M | ||||
Shares Owned By Insiders | 0.94 % | ||||
Shares Owned By Institutions | 87.54 % | ||||
Number Of Shares Shorted | 13.09 M | ||||
Price To Earning | 16.74 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kellanova. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Kellanova Stock please use our How to buy in Kellanova Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Kellanova Stock analysis
When running Kellanova's price analysis, check to measure Kellanova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kellanova is operating at the current time. Most of Kellanova's value examination focuses on studying past and present price action to predict the probability of Kellanova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kellanova's price. Additionally, you may evaluate how the addition of Kellanova to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Stocks Directory Find actively traded stocks across global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Kellanova's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kellanova. If investors know Kellanova will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kellanova listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 2.34 | Earnings Share 2.25 | Revenue Per Share 38.359 | Quarterly Revenue Growth (0.17) |
The market value of Kellanova is measured differently than its book value, which is the value of Kellanova that is recorded on the company's balance sheet. Investors also form their own opinion of Kellanova's value that differs from its market value or its book value, called intrinsic value, which is Kellanova's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kellanova's market value can be influenced by many factors that don't directly affect Kellanova's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kellanova's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kellanova is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kellanova's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.